TABLE 3.
Treatment failure
| Failure type | Failure rate (no. [%])by faldaprevir treatment duration |
|||||
|---|---|---|---|---|---|---|
| 12 wk |
24 wk |
|||||
| GT-1a (n = 40) | GT-1b (n = 39) | Total (n = 81a) | GT-1a (n = 29) | GT-1b (n = 48) | Total (n = 78b) | |
| Virologic breakthroughc | 6 (15.0) | 3 (7.7) | 10a (12.3) | 3 (10.3) | 4 (8.3) | 7 (9.0) |
| During FDV plus PegIFN/RBV | 1 (2.5) | 3 (7.7) | 5a (6.2) | 3 (10.3) | 4 (8.3) | 7 (9.0) |
| During PegIFN/RBV only | 5 (12.5) | 0 | 5 (6.2) | 0 | 0 | 0 |
| Relapsed | 4 (10.0) | 1 (2.6) | 5 (6.2) | 2 (6.9) | 4 (8.3) | 6 (7.7) |
| Othere | 9 (22.5) | 3 (7.7) | 12 (14.8) | 3 (10.3) | 4 (8.3) | 7 (9.0) |
a
GT-1g, n = 1 (had virologic breakthrough); GT-6e, n = 1 (achieved SVR).
b
GT-1g, n = 1 (achieved SVR).
c
HCV RNA rebound of ≥1 log10 from nadir or rebound to ≥100 IU/ml if nadir HCV RNA was undetectable on treatment; confirmed in a second sample.
d
Rebound posttreatment after HCV RNA was undetectable at the end of treatment; confirmed in second sample.
e
Lost to follow-up, SVR result missing, other rebound (defined as confirmed rebound posttreatment when HCV RNA was detectable at the end of treatment), or any other SVR failure not described above.